Kiora Pharmaceuticals KPRX Institutional Ownership

Ownership Summary

Kiora Pharmaceuticals Inc (NASDAQ:KPRX) has 17 institutional investors with active 13F positions as of March 2026.

• Their combined ownership stood at 8.1% of outstanding shares in March 2026, down from 21.0% in December 2025.
• They decreased total shares held in Kiora Pharmaceuticals by -14.14% from last quarter, and the number of investors in KPRX decreased 10.53% annually.
• Of these 17 funds, 11 grew their exposure to Kiora Pharmaceuticals, 2 cut back, and 4 maintained positions.
• In total, institutional investors held 339.18K shares in Kiora Pharmaceuticals as of March 2026, down by 55.88K shares quarter on quarter, and down 946.22K shares year over year.
• ADAR1 Capital Management, LLC leads ownership in KPRX with 167.94K shares as of March 31, 2026, equal to 4.02% of outstanding shares.
• The biggest buyers of Kiora Pharmaceuticals for the quarter ending March 2026 included CITADEL ADVISORS LLC (27.15K), GEODE CAPITAL MANAGEMENT, LLC (25.84K), VANGUARD CAPITAL MANAGEMENT LLC (19.86K), VANGUARD FIDUCIARY TRUST CO (13.03K), TWO SIGMA SECURITIES, LLC (12.02K).
• Top sellers of KPRX stock for the quarter ending March 2026 included ADAR1 Capital Management, LLC (167.94K), Tower Research Capital LLC (TRC) (589).
• Kiora Pharmaceuticals's 10 largest shareholders as of March 2026 include ADAR1 Capital Management, LLC (167.94K), CITADEL ADVISORS LLC (49.53K), GEODE CAPITAL MANAGEMENT, LLC (47.85K), VANGUARD CAPITAL MANAGEMENT LLC (19.86K), XTX Topco Ltd (14.72K), VANGUARD FIDUCIARY TRUST CO (13.03K), TWO SIGMA SECURITIES, LLC (12.02K), Rangeley Capital, LLC (10.0K), Morgan Stanley (1.41K), UBS Group AG (1.3K) per Business Quant data.